Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids

被引:21
作者
Buttgereit, F
Burmester, GR
Brand, MD
机构
[1] Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Hosp, D-10117 Berlin, Germany
[2] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England
关键词
quiescent and stimulated lymphocytes; energy metabolism; concanavalin A; mitogenic stimulation; high dose glucocorticoids; therapeutic effects;
D O I
10.1016/S0006-2952(99)00273-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lymphocytes use a considerable amount of energy, mainly in the form of ATP, especially when they become stimulated following activation by antibodies or mitogens. Cellular respiration is the major energy source, and in quiescent cells the ATP produced is used to drive protein synthesis and sodium transport. In stimulated cells there is significantly higher ATP production to balance the higher ATP demand of specific processes resulting from activation. The major ATP-consuming processes under these conditions are protein synthesis and Na+, K+-ATPase (about 20% each), while Ca2+-ATPase and RNA/DNA syntheses contribute about 10% each. There is a wealth of available information about glucocorticoid effects on lymphocytes, but here we focus on the extent to which this lymphocyte bioenergetic machinery is targeted by glucocorticoids when they are used therapeutically at high doses. High-dose glucocorticoids have been shown recently to interfere with processes that are essential for the activation and maintenance of lymphocytes, such as sodium and potassium transport. Therefore, in this article we describe the bioenergetics of lymphocytes in resting, activated, and glucocorticoid-treated states and present a concept for discussion to describe the relationship among these states in fundamental and clinical terms. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:597 / 603
页数:7
相关论文
共 37 条
[1]  
Atkinson D, 1977, CELLULAR ENERGY META, P218
[2]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[3]   GLUCOCORTICOID THERAPY FOR IMMUNE-MEDIATED DISEASES - BASIC AND CLINICAL CORRELATES [J].
BOUMPAS, DT ;
CHROUSOS, GP ;
WILDER, RL ;
CUPPS, TR ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (12) :1198-1208
[4]   THE CAUSES AND FUNCTIONS OF MITOCHONDRIAL PROTON LEAK [J].
BRAND, MD ;
CHIEN, LF ;
AINSCOW, EK ;
ROLFE, DFS ;
PORTER, RK .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 1994, 1187 (02) :132-139
[5]   ON THE NATURE OF THE MITOCHONDRIAL PROTON LEAK [J].
BROWN, GC ;
BRAND, MD .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1059 (01) :55-62
[6]   Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: A novel glucocorticoid hierarchy [J].
Buttgereit, F ;
Brand, MD ;
Burmester, GR .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (02) :363-368
[7]  
BUTTGEREIT F, 1991, BIOCHEM INT, V24, P59
[8]   Methylprednisolone inhibits uptake of Ca2+ and Na+ ions into concanavalin A-stimulated thymocytes [J].
Buttgereit, F ;
Krauss, S ;
Brand, MD .
BIOCHEMICAL JOURNAL, 1997, 326 :329-332
[9]   CONA INDUCED CHANGES IN ENERGY-METABOLISM OF RAT THYMOCYTES [J].
BUTTGEREIT, F ;
BRAND, MD ;
MULLER, M .
BIOSCIENCE REPORTS, 1992, 12 (05) :381-386
[10]   THE INFLUENCE OF METHYLPREDNISOLONE ON THE ENERGY-METABOLISM OF EHRLICH ASCITES TUMOR-CELLS [J].
BUTTGEREIT, F ;
MULLER, M ;
WOLBART, K ;
THIELE, B ;
HIEPE, F .
BIOSCIENCE REPORTS, 1994, 14 (06) :283-290